International Stem Cell (ISCO) EBITDA Margin Growth (5y) (2015 - 2026)
International Stem Cell (ISCO) EBITDA Margin Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - |
| 10 | International Stem Cell | 3.20 Mn | 2.11 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,084.00 |
| Dec 31, 2025 | 3,514.00 |
| Sep 30, 2025 | 5,785.00 |
| Jun 30, 2025 | 5,274.00 |
| Mar 31, 2025 | 918.00 |
| Dec 31, 2024 | 8,964.00 |
| Sep 30, 2024 | 3,466.00 |
| Jun 30, 2024 | 4,693.00 |
| Mar 31, 2024 | 5,877.00 |
| Dec 31, 2023 | 3,423.00 |
| Sep 30, 2023 | 1,583.00 |
| Jun 30, 2023 | 426.00 |
| Mar 31, 2023 | 4,510.00 |
| Dec 31, 2022 | 10,696.00 |
| Sep 30, 2022 | 3,490.00 |
| Jun 30, 2022 | 5,840.00 |
| Mar 31, 2022 | 5,341.00 |
| Dec 31, 2021 | 5,188.00 |
| Sep 30, 2021 | 3,113.00 |
| Jun 30, 2021 | 4,304.00 |